Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citation
Cited by
Items 401–500 of 1,003
Vincelette, J., da Cunha, V., Martin-McNulty, B., Mallari, C. R., Fitch, R. M., Alexander, S., Islam, I., Buckman, B. O., Yuan, S., Post, J., et al. (2007) · Thrombosis and Haemostasis · doi:10.1160/th06-12-0732 · Cited by 43
Druggability predictions: methods, limitations, and applications
Barril, X. (2012) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1134 · Cited by 46
Balazs, A., Carbajo, R. J., Davies, N. L., Dong, Y., Hird, A. W., Johannes, J. W., Lamb, M. L., McCoull, W., Raubo, P., Robb, G. R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00716 · Cited by 43
Hughes, A. D., & Jones, L. H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.106 · Cited by 44
Golden, A. P., Li, N., Chen, Q., Lee, T., Nevill, T., Cao, X., Johnson, J., Erdemli, G., Ionescu‐Zanetti, C., Urbán, L., et al. (2011) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0362 · Cited by 42
Identification of Type II and III DDR2 Inhibitors
Richters, A., Nguyen, H. D., Phan, T. T. P., Simard, J. R., Grütter, C., Engel, J., & Rauh, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500167q · Cited by 42
Kinetic efficiency: the missing metric for enhancing compound quality?
Holdgate, G., & Gill, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.006 · Cited by 42
Comeo, E., Kindon, N. D., Soave, M., Stoddart, L. A., Kilpatrick, L. E., Scammells, P. J., Hill, S. J., & Kellam, B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01856 · Cited by 46
Lai, C., Li, H., Yu, W., Shah, S., Bommineni, G. R., Perrone, V., García–Díaz, M., Tonge, P. J., & Simmerling, C. L. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00284 · Cited by 42
Yin, N., Pei, J., & Lai, L. (2013) · Molecular BioSystems · doi:10.1039/c3mb25471b · Cited by 42
Sommer, R., Hauck, D., Varrot, A., Wagner, S., Audfray, A., Prestel, A., Möller, H. M., Imberty, A., & Titz, A. (2015) · ChemistryOpen · doi:10.1002/open.201500162 · Cited by 42
Guidelines for manuscript submission in the peer-reviewed pharmacological literature
Mullane, K., Enna, S. J., Piette, J. G., & Williams, M. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.023 · Cited by 44
Characterization of 12 GnRH peptide agonists – a kinetic perspective
Nederpelt, I., Georgi, V., Schiele, F., Nowak‐Reppel, K., Fernández‐Montalván, A. E., IJzerman, A. P., & Heitman, L. H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13342 · Cited by 41
Deng, H., Sun, H., & Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.07.005 · Cited by 44
Cell membranes… and how long drugs may exert beneficial pharmacological activityin vivo
Vauquelin, G. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12996 · Cited by 44
A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy
Daryaee, F., Zhang, Z., Gogarty, K. R., Li, Y., Merino, J., Fisher, S. L., & Tonge, P. J. (2017) · Chemical Science · doi:10.1039/c6sc03306g · Cited by 42
Quantitative Ranking of Ligand Binding Kinetics with a Multiscale Milestoning Simulation Approach
Jagger, B. R., Lee, C. T., & Amaro, R. E. (2018) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.8b02047 · Cited by 41
Krasavin, M., Kalinin, S., Sharonova, T. V., & Supuran, C. T. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1801674 · Cited by 41
Lenina, O. A., Zueva, I. V., Васильевич, З. В., Semenov, V. E., Masson, P., & Petrov, K. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-73822-6 · Cited by 41
Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity
Moreno–Yruela, C., & Olsen, C. A. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00702 · Cited by 44
Markovian Weighted Ensemble Milestoning (M-WEM): Long-Time Kinetics from Short Trajectories
Ray, D., Stone, S. E., & Andricioaei, I. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00803 · Cited by 49
Unbinding Pathways of VEGFR2 Inhibitors Revealed by Steered Molecular Dynamics
Capelli, A. M., & Costantino, G. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500527j · Cited by 41
From a Library of MAG Antagonists to Nanomolar CD22 Ligands
Mesch, S., Lemme, K., Wittwer, M., Koliwer‐Brandl, H., Schwardt, O., Kelm, S., & Ernst, B. (2011) · ChemMedChem · doi:10.1002/cmdc.201100407 · Cited by 41
Determination of Slow-binding HDAC Inhibitor Potency and Subclass Selectivity
Moreno-Yruela, C., & Olsen, C. A. (2021) · doi:10.1101/2021.12.18.473277 · Cited by 41
“We selected four inhibitors for our investigations; SAHA (1), entinostat (3), RGFP966 (4), and acylhydrazide 5.24 Compounds 1 and 3 inhibit HDACs 1–3 with similar potency in end-point assays, while they display different kinetics of inhibition (fast- and slow-binding kinetics, respectively).15, 17, 25 Compounds 4 and…”
BackgroundMethodInfluentialHIV Drug Resistance and the Advent of Integrase Inhibitors
Quashie, P. K., Mésplède, T., & Wainberg, M. A. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0305-1 · Cited by 46
1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus
Nyanguile, O., Devogelaere, B., Vijgen, L., den Broeck, W. M. M. V., Pauwels, F., Cummings, M. D., Bondt, H. L. D., Vos, A. M., Berke, J. M., Lenz, O., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01980-09 · Cited by 40
Seow, V., Lim, J., Cotterell, A. J., Yau, M., Xu, W., Lohman, R., Kok, W. M., Stoermer, M. J., Sweet, M. J., Reid, R. C., et al. (2016) · Scientific Reports · doi:10.1038/srep24575 · Cited by 40
Bosma, R., van den Bor, J., Vischer, H. F., Labeaga, L., & Leurs, R. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.011 · Cited by 40
On the influence of protein binding on pharmacological activity of drugs
Berezhkovskiy, L. M. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21958 · Cited by 40
Substituted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization
Tasler, S., Müller, O., Wieber, T., Herz, T., Pegoraro, S., Saeb, W., Lang, M., Krauss, R., Totzke, F., Zirrgiebel, U., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.047 · Cited by 40
Xing, W., Ai, J., Jin, S., Shi, Z., Xia, P., Wang, L., Ji, Y., Lu, D., Liu, Y., Geng, M., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.041 · Cited by 40
Garvey, E. P., Schwartz, B. J., Gartland, M. J., Lang, S., Halsey, W. S., Sathe, G. M., Carter, H. L., & Weaver, K. L. (2009) · Biochemistry · doi:10.1021/bi802141y · Cited by 40
Fragment-based discovery of focal adhesion kinase inhibitors
Grädler, U., Bomke, J., Müsil, D., Dresing, V., Lehmann, M., Hölzemann, G., Greiner, H. E., Esdar, C., Krier, M., & Heinrich, T. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.050 · Cited by 40
Getlik, M., Grütter, C., Simard, J. R., Nguyen, H. D., Robubi, A., Aust, B., van Otterlo, W. A. L., & Rauh, D. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.11.019 · Cited by 43
THE INNOVATIVE MEDICINES INITIATIVE: A PUBLIC PRIVATE PARTNERSHIP MODEL TO FOSTER DRUG DISCOVERY
Vaudano, E. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201303017 · Cited by 43
Kopec, K. K., Flood, D. G., Ga̧sior, M., McKenna, B. A., Zuvich, E., Schreiber, J., Salvino, J. M., Durkin, J. T., Ator, M. A., & Marino, M. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.004 · Cited by 40
Danielson, U. H. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.100 · Cited by 40
Holas, O., Ondrejček, P., & Doležal, M. (2014) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2014.959512 · Cited by 40
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery
Zech, S. G., Kohlmann, A., Zhou, T., Li, F., Squillace, R. M., Parillon, L., Greenfield, M. T., MILLER, D. P., Qi, J., Thomas, R. M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01552 · Cited by 40
Dickson, C. J., Horn̆ák, V., Velez‐Vega, C., McKay, D. J., Reilly, J., Sandham, D. A., Shaw, D., Fairhurst, R. A., Charlton, S. J., Sykes, D. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00358 · Cited by 41
Shapiro, G. I., McCallum, S. W., Adams, L. M., Sherman, L. J., Weller, S., Swann, S., Keer, H. N., Miles, D., Müller, T. R., Rabe, D. C., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0287-6 · Cited by 40
A Chemical Biology Approach to the Chaperome in Cancer—HSP90 and BeyondPreprint
Taldone, T., Wang, T., Rodina, A., Pillarsetty, N., Digwal, C. S., Sharma, S., Yan, P., Joshi, S., Pagare, P. P., Bolaender, A., et al. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034116 · Cited by 40
Hilimire, T. A., Bennett, R. P., Stewart, R. A., García‐Miranda, P., Blume, A., Becker, J. T., Sherer, N. M., Helms, E. D., Butcher, S. E., Smith, H. C., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00682 · Cited by 39
Cummings, M. D., Lin, T., Hu, L., Tahri, A., McGowan, D. C., Amssoms, K., Last, S., Devogelaere, B., Rouan, M. C., Vijgen, L., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401396p · Cited by 39
Cummings, M. D., Lin, T., Hu, L., Tahri, A., McGowan, D. C., Amssoms, K., Last, S., Devogelaere, B., Rouan, M. C., Vijgen, L., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200110 · Cited by 39
Compound high-quality criteria: a new vision to guide the development of drugs, current situation
Mignani, S. M., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.005 · Cited by 46
Rudolph, J., Xiao, Y., Pardi, A., & Ahn, N. G. (2014) · Biochemistry · doi:10.1021/bi501101v · Cited by 41
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 42
Homogeneous, Real-Time NanoBRET Binding Assays for the Histamine H3 and H4 Receptors on Living Cells
Mocking, T. A. M., Verweij, E. W. E., Vischer, H. F., & Leurs, R. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.113373 · Cited by 39
Toward High-Throughput Predictive Modeling of Protein Binding/Unbinding Kinetics
Chiu, S. H., & Xie, L. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00632 · Cited by 43
Measles Resurgence and Drug Development
Plemper, R. K. (2020) · Current Opinion in Virology · doi:10.1016/j.coviro.2020.02.007 · Cited by 39
Badaoui, M., Buigues, P. J., Berta, D., Mandana, G. M., Gu, H., Földes, T., Dickson, C. J., Horn̆ák, V., Kato, M., Molteni, C., et al. (2022) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00924 · Cited by 42
Thiolactomycin-based β-Ketoacyl-AcpM Synthase A (KasA) Inhibitors
Kapilashrami, K., Bommineni, G. R., Machutta, C. A., Kim, P., Lai, C., Simmerling, C. L., Picart, F., & Tonge, P. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.414516 · Cited by 39
Smith, G. F. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04801-2 · Cited by 42
Kitir, B., Maolanon, A. R., Ohm, R. G., Colaço, A. R., Fristrup, P., Madsen, A. S., & Olsen, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00725 · Cited by 38
Structural Basis and Binding Kinetics of Vaborbactam in Class A β-Lactamase Inhibition
Pemberton, O. A., Tsivkovski, R., Totrov, M. M., Lomovskaya, O., & Chen, Y. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00398-20 · Cited by 38
Conflitti, P., Raniolo, S., & Limongelli, V. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00641 · Cited by 44
Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery
Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.004 · Cited by 38
Wittenberg, N. J., Im, H., Xu, X., Wootla, B., Watzlawik, J. O., Warrington, A. E., Rodriguez, M., & Oh, S. (2012) · Analytical Chemistry · doi:10.1021/ac300819a · Cited by 38
Mechanism of the Association Pathways for a Pair of Fast and Slow Binding Ligands of HIV-1 Protease
Huang, Y. M., Raymundo, M. A. V., Chen, W., & Chang, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.6b01112 · Cited by 39
Glas, A., Wamhoff, E., Krüger, D. M., Rademacher, C., & Grossmann, T. N. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201702776 · Cited by 39
Walter, N. M., Wentsch, H. K., Bührmann, M., Bauer, S. M., Döring, E., Mayer‐Wrangowski, S. C., Sievers‐Engler, A., Willemsen‐Seegers, N., Zaman, G. J. R., Buijsman, R. C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00745 · Cited by 38
Lü, H., Iuliano, J. N., & Tonge, P. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.002 · Cited by 39
The implications of target saturation for the use of drug–target residence time
de Witte, W. E. A., Danhof, M., van der Graaf, P. H., & de Lange, E. C. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.234 · Cited by 38
Todsaporn, D., Mahalapbutr, P., Poo-arporn, R. P., Choowongkomon, K., & Rungrotmongkol, T. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105787 · Cited by 42
Nguyen, P.-C., Lewis, K. B., Ettinger, R. A., Schuman, J. T., Lin, J. C., Healey, J. F., Meeks, S. L., Lollar, P., & Pratt, K. P. (2014) · Blood · doi:10.1182/blood-2013-09-527275 · Cited by 38
Hasenhuetl, P. S., Schicker, K. W., Koenig, X., Li, Y., Sarker, S., Stockner, T., Sučić, S., Sitte, H. H., Freissmuth, M., & Sandtner, W. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099036 · Cited by 38
A unique peptide deformylase platform to rationally design and challenge novel active compounds
Fieulaine, S., de Sousa, R. A., Maigre, L., Hamiche, K., Alimi, M., Bolla, J., Taleb, A., Denis, A., Pagès, J., Artaud, I., et al. (2016) · Scientific Reports · doi:10.1038/srep35429 · Cited by 38
Yu, Z., IJzerman, A. P., & Heitman, L. H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12967 · Cited by 37
ElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 38
Iwata, H., Imamura, S., Hori, A., Hixon, M. S., Kimura, H., & Miki, H. (2010) · Biochemistry · doi:10.1021/bi101777f · Cited by 37
Deng, H., Wang, C., Su, M., & Ye, F. (2012) · Analytical Chemistry · doi:10.1021/ac301495n · Cited by 37
Kinetic operational models of agonism for G-protein-coupled receptors
Hoare, S. R. J., Pierre, N., Moya, A. G., & Larson, B. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.02.014 · Cited by 40
Double-Modified Glycopolymers from Thiolactones to Modulate Lectin Selectivity and Affinity
Wilkins, L. E., Badi, N., Prez, F. D., & Gibson, M. I. (2018) · ACS Macro Letters · doi:10.1021/acsmacrolett.8b00825 · Cited by 37
Selective binding of a toxin and phosphatidylinositides to a mammalian potassium channel
Liu, Y., LoCaste, C. E., Liu, W., Poltash, M. L., Russell, D. H., & Laganowsky, A. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09333-4 · Cited by 38
Andersen, J., Ringsted, K. B., Bang‐Andersen, B., Strømgaard, K., & Kristensen, A. S. (2015) · Scientific Reports · doi:10.1038/srep15650 · Cited by 39
Chu, X., & Wang, J. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003782 · Cited by 39
Peuker, S., Cukkemane, A., Held, M., Noé, F., Kaupp, U. B., & Seifert, R. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2012.11.3816 · Cited by 43
Charnley, A. K., Convery, M. A., Shah, A. L., Jones, E. J., Hardwicke, P., Bridges, A. M., Ouellette, M. T., Totoritis, R. D., Schwartz, B. K., King, B. W., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.09.038 · Cited by 37
Hoare, S. R. J., Fleck, B. A., Williams, J. P., & Grigoriadis, D. E. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.011 · Cited by 36
Han, S., Li, X., Xia, Y., Yu, Z., Cai, N., Malwal, S. R., Han, X., Oldfield, E., & Zhang, Y. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01405 · Cited by 36
A Supervised Molecular Dynamics Approach to Unbiased Ligand–Protein Unbinding
Deganutti, G., Moro, S., & Reynolds, C. A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01094 · Cited by 37
Lee, K. S. S., Ng, J. C., Yang, J., Hwang, S., Morisseau, C. H. P., Wagner, K. M., & Hammock, B. D. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115735 · Cited by 36
Fischer, S., Wentsch, H. K., Mayer‐Wrangowski, S. C., Zimmermann, M. O., Bauer, S. M., Storch, K., Nieß, R., Koeberle, S. C., Grütter, C., Boeckler, F. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301539x · Cited by 36
Winquist, J., Geschwindner, S., Xue, Y., Gustavsson, L., Müsil, D., Deinum, J., & Danielson, U. H. (2013) · Biochemistry · doi:10.1021/bi301333z · Cited by 38
SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial Agonism
van Marrewijk, L. M., Polyak, S. W., Hijnen, M., Kuruvilla, D. S., Chang, M. R., Shin, Y., Kamenecka, T. M., Griffin, P. R., & Bruning, J. B. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00580 · Cited by 42
Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics
Riviere, J. E., Gabrielsson, J., Fink, M., & Mochel, J. P. (2015) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12278 · Cited by 37
A Multiscale Simulation Approach to Modeling Drug–Protein Binding Kinetics
Haldar, S., Comitani, F., Saladino, G., Woods, C. J., van der Kamp, M. W., Mulholland, A. J., & Gervasio, F. L. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00687 · Cited by 38
Covalent Inhibition Mechanism of Antidiabetic Drugs—Vildagliptin vs Saxagliptin
Wang, Y., Zhang, F., Diao, H., & Wu, R. (2019) · ACS Catalysis · doi:10.1021/acscatal.8b05051 · Cited by 35
Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases
Benn, C., Gibson, K. R., & Reynolds, D. S. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200421 · Cited by 39
Baseline Model for Predicting Protein–Ligand Unbinding Kinetics through Machine Learning
Amangeldiuly, N., Karlov, D. S., & Fedorov, M. V. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00450 · Cited by 35
Zhang, P., Zhou, X., Jiang, J., Kolay, J., Wang, R., Ma, G., Wan, Z., & Wang, S. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202209469 · Cited by 35
Wolf, S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00151 · Cited by 38
Alexander, C. (2008) · Nature Materials · doi:10.1038/nmat2281 · Cited by 35
Understanding ligand-receptor non-covalent binding kinetics using molecular modeling
Chang, C. A. (2016) · Frontiers in bioscience · doi:10.2741/4527 · Cited by 37
Residence time in drug discovery: current insights and future perspectives
Kordylewski, S. K., Bugno, R., & Podlewska, S. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00748-z · Cited by 38
Palde, P. B., Ofori, L. O., Gareiss, P. C., Lerea, J., & Miller, B. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100231t · Cited by 34
Glossop, P. A., Watson, C. A. L., Price, D. A., Bunnage, M. E., Middleton, D. S., Wood, A., James, K., Roberts, D. F., Strang, R. S., Yeadon, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200884j · Cited by 34
In vivo potency revisited – Keep the target in sight
Gabrielsson, J., Peletier, L. A., & Hjorth, S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.011 · Cited by 35
Atomic Force Microscopy in Probing Tumor Physics for Nanomedicine
Li, M., Xi, N., Wang, Y., & Liu, L. (2018) · IEEE Transactions on Nanotechnology · doi:10.1109/tnano.2018.2882383 · Cited by 35
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.